
AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery techno... AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements. Show more
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 2.81 | 19.459833795 | 14.44 | 17.41 | 13.99 | 676275 | 16.26305141 | CS |
4 | 4.26 | 32.7944572748 | 12.99 | 21.57 | 12.21 | 1504063 | 16.96634224 | CS |
12 | 0.76 | 4.60885385082 | 16.49 | 21.57 | 12.21 | 959640 | 16.24399258 | CS |
26 | -17.54 | -50.4167864329 | 34.79 | 40.7 | 12.21 | 706951 | 19.74101239 | CS |
52 | -7.7 | -30.8617234469 | 24.95 | 41.3083 | 12.21 | 531095 | 22.20903387 | CS |
156 | -11.76 | -40.537745605 | 29.01 | 41.3083 | 12.21 | 350447 | 22.29694382 | CS |
260 | 1.28 | 8.01502817783 | 15.97 | 41.3083 | 12.06 | 330296 | 22.51796626 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales